Antiviral composition containing material involved in phosphatidylcholine synthesis pathway

US10092587B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10092587-B2
Application numberUS-201615389248-A
CountryUS
Kind codeB2
Filing dateDec 22, 2016
Priority dateJun 25, 2014
Publication dateOct 9, 2018
Grant dateOct 9, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to an antiviral composition comprising any one selected from the group consisting of chlorine, phosphocholine, cytidine triphosphate, CDP-choline, phosphorylcholine, and phosphatidylcholine. The antiviral composition is harmless to the human body and exhibits an excellent inhibitory effect on virus proliferation. Therefore, it can be applied to a pharmaceutical composition for preventing or treating viral diseases as well as a health functional food, a quasi-drug composition, and a feed composition for preventing or ameliorating viral diseases.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of enhancing antiviral activity in a subject infected by a virus, comprising administering an antiviral composition to the subject, wherein the virus belongs to the family picornaviridae and the composition comprises at least one substance involved in phosphatidyl synthesis pathway, selected from the following group: i) choline; ii) phosphocholine; iii) cytidine diphosphate-choline (CDP-choline); iv) phosphorylcholine; and v) phosphatidylcholine. 2. The method of claim 1 , wherein the composition further comprises cytidine triphosphate (CTP). 3. The method of claim 1 , wherein the virus is any one selected from the group consisting of rhinovirus, enterovirus, cardiovirus, aphthovirus , and hepatovirus. 4. The method of claim 3 , wherein the rhinovirus is any one selected from the group consisting of rhinovirus type 2, type 3, and type 5. 5. The method of claim 3 , wherein the enterovirus is coxsackievirus type A or coxsackievirus type B. 6. A method for treating a subject infected by a viral disease, comprising administrating an antiviral composition to the subject, wherein the virus belongs to the family picornaviridae and the composition comprises at least one substance involved in phosphatidyl synthesis pathway, selected from the following group: i) choline; ii) phosphocholine; iii) cytidine diphosphate-choline (CDP-choline); iv) phosphorylcholine; and v) phosphatidylcholine. 7. The method of claim 6 for treating a viral disease, wherein the viral disease comprises any one selected from the group consisting of cold, enteritis, hand-foot-mouth disease, viral meningitis, pneumonia, encephalitis, neurogenic pulmonary edema, conjunctivitis, encephalomyocarditis, myocarditis, hepatitis, poliomyelitis, paralysis, vesicular disease, myositis, pancreatitis, epidemic myalgia, herpangina, asthma, chronic obstructive pulmonary disease, sinusitis, and tympanitis. 8. The method of claim 6 for treating a viral disease, wherein the viral disease is a cold. 9. The method of claim 6 , wherein the composition further comprises cytidine triphosphate (CTP). 10. A method of enhancing antiviral activity in a subject, comprising administering an antiviral composition to the subject infected by a virus, wherein the virus is any one selected from the group consisting of rhinovirus type 2, rhinovirus type 3, rhinovirus type 5, coxsackievirus type A and coxsackievirus type B, and the composition comprises cytidine triphosphate (CTP).

Assignees

Inventors

Classifications

  • Compounds containing phosphorus · CPC title

  • Sugars; Polysaccharides · CPC title

  • having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

  • containing six-membered rings with nitrogen as a ring hetero atom · CPC title

  • Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10092587B2 cover?
The present invention relates to an antiviral composition comprising any one selected from the group consisting of chlorine, phosphocholine, cytidine triphosphate, CDP-choline, phosphorylcholine, and phosphatidylcholine. The antiviral composition is harmless to the human body and exhibits an excellent inhibitory effect on virus proliferation. Therefore, it can be applied to a pharmaceutical com…
Who is the assignee on this patent?
Korea Res Inst Bioscience & Biotechnology
What technology area does this patent fall under?
Primary CPC classification A61K31/7056. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).